Material Agreement Form 8 K

On September 17, 2024, ARS Pharmaceuticals Operations, Inc. ("ARS OpCo"), a wholly-owned subsidiary of ARS Pharmaceuticals, Inc. (collectively with ARS OpCo, the "Company"), entered into the second amendment (the "Amendment") to its manufacturing agreement with Renaissance Lakewood, LLC ("Renaissance"), dated as of September 9, 2020 and amended as of July 25, 2023 (as amended by the Amendment, the "Agreement"). Pursuant to the Amendment, among other things, the parties:

(i) revised the term of the Agreement such that the initial term commenced on the date it was entered into and continues (a) for neffynasal unit dose sprays ("Product") designated for commercial sale in the U.S. on December 31st immediately following the five year anniversary of the U.S. initial launch date, and (b) for Product designated for commercial sale in the E.U., on December 31st immediately following the five year anniversary of the E.U. initial launch date, unless sooner terminated pursuant to the Agreement, with the initial terms automatically renewing for successive two-yearterms, unless either party gives notice pursuant to the Agreement; and

(ii) revised the termination provisions of the Agreement such that either party may terminate the agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-productbasis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if: (a) the Company's authorization and approval to distribute or sell Product in the U.S. is not granted on or before a specified date, (b) the Company's authorization and approval representing more than a certain number of units of Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company at its sole discretion determines to cease commercializing all Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.

Forward-Looking Statements

This report contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: the ability to maintain regulatory approval for neffy; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from neffy; neffy may fail to achieve the degree of market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community necessary for commercial success; if the Company is unable to fully develop sales, marketing and distribution capabilities, it may not be successful in commercializing neffy; the labeling for neffyin any future indication or patient population; the scope, progress and expansion of developing and commercializing neffy; the potential for payors to delay, limit or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-visintramuscular injectable products; the scope, progress and expansion of developing and commercializing neffy, including the ability to enter into distribution and/or partnering arrangements and obtain favorable reimbursement; the Company's ability to protect its intellectual property position; and the impact of government laws, prescription drug price controls and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q forthe quarter ended June 30, 2024, filed with the SEC on August 6, 2024.